Author

Pete Newham

Institution: AstraZeneca (United Kingdom)

Observed institution: AstraZeneca (United Kingdom)

OpenAlex ID: A5045757643

Proteolysis‐targeting chimeras in drug development: A safety perspective

2020 · Kevin Moreau, Muireann Coen, et al. · British Journal of Pharmacology · 237

Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized

2009 · David J Hunter, Lou Gerstenfeld, et al. · Arthritis Research & Therapy · 219

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

2004 · Andrew Baxter, Steve Brough, et al. · Bioorganic & Medicinal Chemistry Letters · 89

Bromodomain and extraterminal (BET) domain inhibitors induce a loss of intestinal stem cells and villous atrophy

2014 · Matt Wagoner, Janet Kelsal, et al. · Toxicology Letters · 6

The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator

2016 · Claire Grant, Lorna Ewart, et al. · Toxicology and Applied Pharmacology · 4

Stem cells, organoids and microphysiological systems coupled to modeling & simulation guide drug discovery and enhance translational safety risk assessment

2017 · Pete Newham · Toxicology Letters

Modifying the risk-benefit ratio using drug delivery systems

2013 · Pete Newham · Toxicology Letters

Works count: 8

Citation count: 555

H-index: 4

I10-index: 3